FG-2216: Phase II data

In a U.S. Phase II trial, twice-weekly oral doses of 375, 625 and 1,250 mg of FG-2216 led to Hb responses, defined as increases of 1 g/dL, in 13 (50%), 31 (60%) and 38 (76%) of patients vs. none for p...